source
- Bristol Myers' lung drug admilparant meets Phase 3 goal at low dose, high dose falls shortBristol Myers Squibb reported that its experimental idiopathic pulmonary fibrosis therapy admilparant achieved its primary endpoint in a Phase 3 trial, showing a statistically significant slowing o…
- BMS lung drug meets low-dose endpoint in Phase 3 but high dose fails to improve lung functionBristol Myers Squibb reported that its LPA1 antagonist admilparant achieved the primary endpoint in a Phase 3 idiopathic pulmonary fibrosis study at the 60‑mg dose, showing a statistically signific…